Ken Griffin Poseida Therapeutics, Inc. Transaction History

Citadel Advisors LLC

$509 Billion
Q1 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Poseida Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 93,000 shares of PSTX stock, worth $271,560. This represents 0.0% of its overall portfolio holdings.

Number of Shares

93,000

Holding current value

$271,560

% of portfolio

0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$2.76 - $4.13 $177,810 - $266,071	64,424 New	64,424 $205,000
Q3 2023 Nov 14, 2023	SELL	$1.62 - $2.79 $141,456 - $243,620	-87,319 Reduced 99.15%	746 $1,000
Q2 2023 Aug 14, 2023	SELL	$1.66 - $3.4 $238,108 - $487,692	-143,439 Reduced 61.96%	88,065 $154,000
Q1 2023 May 15, 2023	BUY	$3.08 - $8.73 $584,556 - $1.66 Million	189,791 Added 454.99%	231,504 $713,000
Q4 2022 Feb 14, 2023	SELL	$4.04 - $6.38 $1.27 Million - $2.01 Million	-315,025 Reduced 88.31%	41,713 $221,000

Q3 2022 Nov 14, 2022	BUY	$2.43 - $4.51 $690,518 - $1.28 Million	284,164 Added 391.55%	356,738 $1.26 Million
Q2 2022 Aug 15, 2022	BUY	$1.87 - $5.0 $101,797 - $272,185	54,437 Added 300.14%	72,574 $187,000
Q1 2022 May 16, 2022	SELL	$3.22 - $7.04 $22,143 - $48,414	-6,877 Reduced 27.49%	18,137 $81,000
Q4 2021 Feb 14, 2022	BUY	$6.23 - $7.6 $26,813 - $32,710	4,304 Added 20.78%	25,014 $170,000
Q2 2021 Aug 16, 2021	SELL	$7.96 - $10.07 $918,170 - $1.16 Million	-115,348 Reduced 84.78%	20,710 $207,000
Q1 2021 May 17, 2021	BUY	$8.51 - $11.91 $1.16 Million - $1.62 Million	136,058 New	136,058 $1.3 Million
Q4 2020 Feb 16, 2021	SELL	$8.29 - $11.7 $369,029 - $520,825	-44,515 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$8.09 - $16.25 $360,126 - $723,368	44,515 New	44,515 $395,000

Others Institutions Holding PSTX

# of Institutions

Shares Held

38.1M

Call Options Held

255K

Put Options Held

62K

View Full List

About Poseida Therapeutics, Inc.

Ticker PSTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 85,775,600
Market Cap $250M
Description
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant ...

More about PSTX

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account